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bers. Multicenter randomized controlled trials on CDH are 
lacking. Use of a standardized protocol, however, may con-
tribute to more valid comparisons of patient data in multi-
center studies and identification of areas for further research. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Congenital diaphragmatic hernia (CDH) is a congeni-
tal anomaly which affects 1 in 3,000 live births  [1] . De-
spite advances in neonatal care, CDH is associated with a 
high risk of mortality and morbidity  [2] . The combina-
tion of pulmonary hypoplasia and abnormal morphology 
of the pulmonary vasculature leads to severe respiratory 
insufficiency in over 90% of cases in the first hours after 
birth. Infants with CDH are at increased risk of develop-
ing persistent pulmonary hypertension of the newborn 
(PPHN) due to a pathological development of the pulmo-
nary vasculature. Several triggers such as hypoxemia, ac-
idosis and pulmonary vascular damage caused by me-
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 Abstract 
 Congenital diaphragmatic hernia (CDH) is associated with 
high mortality and morbidity. To date, there are no standard-
ized protocols for the treatment of infants with this anomaly. 
However, protocols based on the literature and expert opin-
ion might improve outcome. This paper is a consensus state-
ment from the CDH EURO Consortium prepared with the aim 
of achieving standardized postnatal treatment in European 
countries. During a consensus meeting between high-vol-
ume centers with expertise in the treatment of CDH in Eu-
rope (CDH EURO Consortium), the most recent literature on 
CDH was discussed. Thereafter, 5 experts graded the studies 
according to the Scottish Intercollegiate Guidelines Network 
(SIGN) Criteria. Differences in opinion were discussed until 
full consensus was reached. The final consensus statement, 
therefore, represents the opinion of all consortium mem-
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chanical ventilation sustain PPHN through reactive va-
soconstriction and vascular remodeling. Therefore, it 
would seem best to achieve optimal management of ele-
vated pulmonary arterial pressure and prevent further 
damage to the lung before undertaking surgical repair of 
the diaphragmatic defect. 
 Single center experience may not be representative as 
they often include a small number of patients  [3] . A lit-
erature review by Logan et al.  [4] revealed a limited num-
ber of clinical trials examining interventions to improve 
survival of infants with CDH. Recently, Deprest et al.  [5] 
 published a manuscript, together with some experts of 
the CDH EURO Consortium, on the perinatal manage-
ment of isolated CDH. However, there are no extensive 
standardized protocols for the postnatal management of 
CDH. As a consequence, members of the CDH EURO 
Consortium, a collaboration of specialized CDH centers 
in Western Europe, have developed a consensus state-
ment for the postnatal treatment of patients with CDH 
based on the recent literature and expert opinion.
 Members of the CDH EURO Consortium from cen-
ters in which more than 10 infants with CDH are treated 
per year held a consensus meeting. It covered all aspects 
of the treatment of infants with CDH and was based on a 
summary of recent relevant literature. The studies were 
graded according to the Scottish Intercollegiate Guide-
lines Network (SIGN) Criteria  [6] . This grading system is 
based on study design and methodological quality of in-
dividual studies. Five experts individually determined 
the levels of evidence of the literature on the guidance of 
a SIGN-checklist. Four of these have clinical experience 
with CDH and all 5 have scientific schooling and experi-
ence. Differences in opinion were discussed until full 
consensus was reached. The final consensus statement, 
therefore, represents the opinion of all consortium mem-
bers. The levels of evidence and grades of recommenda-
tion according to the SIGN criteria are presented in  ta-
bles 1 and  2 , respectively. 
 Prenatal Diagnosis and Delivery 
 With the increased use of prenatal ultrasound, many 
cases of CDH are now detected before birth. After diag-
nosis, a more detailed evaluation should be performed 
to determine the location of the defect, the absolute and 
observed/expected lung-to-head ratio (O/E LHR), the 
position of the liver and the presence or absence of oth-
er associated congenital anomalies or syndromes  [7, 8] . 
Table 1. L evels of evidence
Level Description of evidence
1++ High quality meta-analyses, systematic reviews of ran-
domized controlled trials, or randomized controlled trials 
with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of ran-
domized controlled trials, or randomized controlled trials 
with a low risk of bias
1– Meta-analyses, systematic reviews or randomized con-
trolled trials, or randomized controlled trials with a high 
risk of bias
2++ High-quality systematic reviews of case-control or cohort 
studies, or high-quality case-control or cohort studies 
with a very low risk of confounding, bias or chance, and a 
high probability that the relationship is causal
2+ Well-conducted case-control or cohort studies with a low 
risk of confounding, bias or chance, and a moderate prob-
ability that the relationship is causal
2– Case-control or cohort studies with a high risk of con-
founding, bias or chance, and a significant risk that the 
relationship is not causal
3 Nonanalytic studies, e.g. case reports, case series
4 Expert opinion
Table 2. G rades of recommendation
Grade Description of grade
A At least 1 meta-analysis, systematic review, or random-
ized controlled trial rated as 1++ and directly applicable 
to the target population, or a systematic review of ran-
domized controlled trials or a body of evidence consisting 
principally of studies rated as 1+ directly applicable to the 
target population and demonstrating overall consistency 
of results
B A body of evidence including studies rated as 2++ direct-
ly applicable to the target population and demonstrating 
overall consistency of results, or extrapolated evidence 
from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+ directly 
applicable to the target population and demonstrating 
overall consistency of results, or extrapolated evidence 
from studies rated as 2++
D Evidence level 3 or 4, or extrapolated evidence from stud-
ies rated as 2+
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In infants with CDH, other associated congenital anom-
alies are present in 10–40% of the cases  [9, 10] . Cardiac 
ano malies are present in about 25% of the infants with 
CDH  [9, 11] .
 If CDH is diagnosed prenatally, an experienced ter-
tiary center with a high case volume may be the optimal 
environment for the delivery and further treatment of an 
infant with CDH. A recent study by Grushka et al. [12] 
has shown that survival was higher in infants born in 
centers that have more than 6 cases a year admitted to 
their ward. There were, however, no differences in the 
need for extracorporeal membrane oxygenation (ECMO) 
treatment or duration of ventilation between centers that 
admitted more than 6 and centers that admitted less than 
6 cases per year  [4, 12] . 
 There is still some doubt about the preferred mode of 
delivery and the timing of delivery in case of a CDH preg-
nancy. Recent studies from the CDH study group report-
ed no significant differences in overall survival between 
patients with CDH born by spontaneous vaginal delivery, 
induced vaginal delivery and elective caesarean section 
 [13, 14] . Survival without the use of ECMO, however, was 
higher for patients born by elective caesarean section ac-
cording to one study  [13] . With regards to the timing of 
delivery, a recent paper by Stevens et al. [14] reported that 
infants with CDH born at a gestational age of 37–38 weeks 
with a birth weight above 3.1 kg had a higher survival 
rate, less need for ECMO and a greater rate of survival if 
ECMO was used than infants with CDH born at a gesta-
tional age of 39–41 weeks. The reason for this difference 
in outcome is not clear, but case selection, differences 
among centers and an increase in pulmonary vascular 
abnormalities in later gestational ages have been pro-
posed as possible explanations  [14] . Earlier data of the 
ELSO Registry reported higher survival rates and a short-
er duration of ECMO treatment in infants born at a ges-
tational age of 40–42 weeks compared to infants with 
CDH born at a gestational age of 38–39 weeks who were 
treated with ECMO  [15] . The best mode and timing of 
delivery in infants with CDH is still unclear and, there-
fore, deserves further study.
 If there is premature labor or a risk of preterm delivery 
between 24 and 34 weeks gestational age, antenatal ste-
roid therapy should be given according to the guidelines 
of the NIH  [16] . Although there are no studies specifi-
cally focusing on this issue in premature infants with 
CDH, the consortium sees no reason to defer from this 
policy as prenatal steroid therapy has been shown to be of 
benefit in babies born prematurely without CDH. Prena-
tal steroid therapy given after a gestational age of 34 
weeks has shown no benefit with regard to survival and 
respiratory outcome in infants with CDH  [17] . 
 Recommendations 
 • Following prenatal diagnosis, the absolute and O/E 
LHR and the position of the liver should be evaluated 
(grade of recommendation = D). 
 • Planned vaginal delivery or cesarean section after a 
gestational age of 37 weeks in a designated tertiary 
center should be pursued (grade of recommenda-
tion = D).  
 • In case of preterm labor prior to 34 weeks of gestation, 
antenatal steroids should be given (grade of recom-
mendation = D).  
 Initial Treatment and Procedures in the Delivery 
Room 
 Initial treatment and procedures in the delivery room 
are based on the Guidelines of the International Consen-
sus on Cardiopulmonary Resuscitation and Emergency 
Cardiovascular Care Science with Treatment Recom-
mendations  [18] . 
 Monitoring and Goal of Treatment 
 Measurements of heart rate, pre- and postductal satu-
rations, and, if necessary, invasive or noninvasive blood 
pressure are recommended. 
 The key principles of successful delivery room resus-
citation and stabilization are the avoidance of high air-
way pressures and the establishment of an adequate pre-
ductal arterial saturation. Previous studies advised keep-
ing preductal arterial saturations between 85% and 95% 
as higher levels may lead to administration of a high oxy-
gen concentration, more aggressive ventilation and a sub-
sequent risk of oxygen toxicity and ventilator-induced 
lung injury  [19–21] . However, some members of the con-
sortium agreed on preductal saturation boundaries in the 
delivery room of 80–95% in infants with CDH based on 
expert opinion. 
 Intubation and Ventilation 
 Although there is no specific evidence, the consortium 
recommends intubating infants with CDH immediately 
after birth. This is done to reduce a possible risk of pul-
monary hypertension due to prolonged acidosis and hy-
poxia which might be caused by delayed intubation. Ven-
tilation by bag and mask may cause distension of the 
stomach and must be avoided as it may limit expansion 
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of the hypoplastic lung. Low peak pressures, preferably 
below 25 cm H 2 O, are given to avoid lung damage to the 
hypoplastic and contralateral lung  [22] . FiO 2 (fraction of 
the oxygen concentration) should be started at 1.0 and 
adjusted downwards to achieve preductal saturations be-
tween 80 and 95%. 
 Nasogastric Tube 
 Immediate placement of an oro- or nasogastric tube 
with continuous or intermittent suction will help to pre-
vent bowel distension and any further lung compression. 
Until surgical repair, continuous suctioning is the recom-
mended procedure to decompress the abdomen. 
 Vascular Access 
 A central or peripheral venous line should be inserted 
to allow the administration of fluids and, if necessary, 
inotropic vasopressor drugs. An arterial line should be 
inserted for blood sampling and monitoring the arterial 
blood pressure; preferably, this should be done in the la-
bor ward. As preductal PaO 2 measurements reflect the 
cerebral oxygenation, the arterial line should be inserted 
into the right radial artery if possible. An umbilical arte-
rial line may be placed, but as this reflects the postductal 
situation, it is less desirable than a right radial artery line.
 Blood Pressure Support 
 In infants with CDH, pulmonary vascular resistance 
remains elevated after birth, resulting in right-to-left 
shunting of blood through the ductus arteriosus and/or 
foramen ovale. This can lead to hypoxemia and acidosis, 
which in turn can perpetuate pulmonary hypertension. 
Measures to increase systemic blood pressure may mini-
mize right-to-left shunting. However, there is no need to 
increase blood pressure levels to supranormal values if 
preductal saturations are between 80 and 95%. Thus, the 
consortium advises to maintain arterial blood pressures 
at normal levels for gestational age  [23] . Only if preductal 
saturations fall below the target values, higher blood 
pressures should be pursued. If there is hypotension and/
or poor perfusion, 10–20 ml/kg NaCl 0.9% should be ad-
ministered once or twice. If perfusion and blood pressure 
do not improve, inotropic and vasopressor agents should 
be considered according to the local practice of the hos-
pital. 
 Sedation and Analgesia  
 There is no specific evidence on sedation and analge-
sia in infants with CDH. However, several investigators 
have studied physiological responses of neonates to awake 
intubation and reported significant rises in systemic arte-
rial blood pressure and intracranial pressure, as well as 
significant decreases in heart rate and transcutaneous 
oxygen saturations  [24] . As soon as venous access is es-
tablished, sedation and analgesia should be started with-
out delay. Careful monitoring of the blood pressure is 
warranted in these situations. There is debate whether 
infants with CDH should receive a neuromuscular block-
ing agent. Indeed, many of the consortium members do 
not routinely paralyze CDH infants.
 Enema 
 Some centers give enemas to infants with CDH with 
the goal to decompress the bowel by inducing defecation. 
There is no evidence that this procedure improves out-
come. 
 Surfactant 
 Preliminary data indicated that surfactant therapy 
may be associated with a higher mortality rate, greater 
use of ECMO therapy and more chronic lung disease in 
infants with CDH  [25] . In preterm infants with CDH, 
surfactant administration was also associated with lower 
survival rate  [26] . Therefore, the routine use of surfactant 
replacement in infants with CDH should be avoided. 
 Recommendations 
 • After delivery, the infant should be intubated imme-
diately without bag and mask ventilation (grade of rec-
ommendation = D). 
 • The goal of treatment in the delivery room is achieving 
acceptable preductal saturation levels between 80 and 
95% (grade of recommendation = D). 
 • Ventilation in the delivery room may be done by con-
ventional ventilator or ventilation bag with a peak 
pressure as low as possible, preferably below 25 cm 
H 2 O (grade of recommendation = D). 
 • An oro-or nasogastric tube with continuous or inter-
mittent suction should be placed (grade of recommen-
dation = D). 
 • Arterial blood pressure has to be maintained at a nor-
mal level for gestational age. In case of hypotension 
and/or poor perfusion, 10–20 ml/kg NaCl 0.9% should 
be administered 1–2 times and inotropic agents should 
be considered (grade of recommendation = D). 
 • Sedatives and analgesics should be given (grade of rec-
ommendation = D). 
 • No routine use of surfactant in either term or preterm 
infants with CDH (grade of recommendation = D). 
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 Ventilation Management in the Intensive Care Unit 
 A ventilation strategy aiming for preductal saturations 
between 85 and 95%, postductal saturation levels above 
70% and arterial CO 2 levels between 45–60 mm Hg (per-
missive hypercapnia) is well accepted. In the first 2 h, pre-
ductal saturation levels as low as 70% may be accepted if 
they are slowly improving without ventilator changes and 
organ perfusion is acceptable, indicated by a pH greater 
than 7.2 and PaCO 2  ! 65 mm Hg  [27, 28] . Thereafter, pre-
ductal saturation levels are preferably kept between 85 
and 95%. In individual cases, however, levels down to 
80% may be accepted, providing organs are well perfused 
as indicated by a pH above 7.2, lactate levels  ! 5 mmol/l 
and urinary output above 1 ml/kg/h. Oxygen toxicity can 
be avoided by decreasing FiO 2 guided by the saturation 
levels described above  [29] . 
 The optimal initial ventilation mode for newborns 
with CDH is not clear. Nevertheless, there is accumulat-
ing evidence that ventilator-induced lung injury may 
have a significant negative impact on outcome in new-
borns with CDH  [30–33] . Permissive hypercapnia and 
‘gentle ventilation’ in neonates with CDH has been re-
ported to increase survival  [29, 34–36] . 
 Conventional Ventilation 
 Until now, the most experience exists with pressure-
controlled ventilation as conventional ventilation mode 
in infants with CDH.
 Based on retrospective studies  [27–29, 35–37] and clin-
ical experience, the consortium recommends limitation 
of peak pressures to 25 cm H 2 O or less, a PEEP (positive 
end-expiratory pressure) of 2–5 cm H 2 O and adjustment 
of the ventilator rate to obtain PaCO 2 levels between 45 
and 60 mm Hg. If a PIP (positive inspiratory pressure) of 
over 28 cm H 2 O is necessary to achieve pCO 2 and satura-
tion levels within the target range, other treatment mo-
dalities should be considered. Weaning from ventilation 
should preferentially be by means of decreasing PIP; fre-
quency and/or the PIP-PEEP should be modified to 
achieve PaCO 2 levels above 45 mm Hg. 
 High-Frequency Oscillatory Ventilation 
 The physiological rationale for use of high-frequency 
oscillatory ventilation (HFOV) derives from its ability to 
preserve end-expiratory lung volume while avoiding 
overdistension, and therefore lung injury, at end-inspira-
tion. Retrospective studies have demonstrated effective 
CO 2 reduction and increased survival in neonates with 
CDH  [38, 39] . However, a prospective randomized con-
trolled trial on the use of HFOV as an initial ventilation 
mode in infants with CDH is still lacking. 
 The indications for HFOV are not clearly defined. 
Mostly it is used as rescue therapy in severe and persist-
ing hypoxemia and hypercapnia on conventional ventila-
tion. In some centers it is the standard initial ventilation 
mode. There is no evidence for the initial settings of 
HFOV in infants with CDH. The mean airway pressure, 
however, should be adjusted to have an adequate expan-
sion of the lungs. A chest radiograph should be performed 
to confirm that the lungs are not overinflated, as defined 
by a contralateral lung expansion such that more than 8 
ribs are visible above the diaphragm  [40] . 
 Chest Radiograph 
 In all patients, a chest radiograph should be made as 
soon as possible to assess the initial condition. Chest ra-
diographs should be repeated guided by the patient’s clin-
ical condition and mode of ventilation.
 Recommendations 
 • Adapt treatment to reach a preductal saturation be-
tween 85 and 95% and a postductal saturation above 
70% (grade of recommendation = D). 
 • In individual cases, preductal saturation above 80% 
might be acceptable, as long as organs are well per-
fused (grade of recommendation = D). 
 • The target PaCO 2 range should be between 45 and 60 
mm Hg (grade of recommendation = D). 
 • Pressure-controlled ventilation: initial settings are a 
PIP of 20–25 cm H 2 O and a PEEP of 2–5 cm H 2 O;
ventilator rate of 40–60/min (grade of recommenda-
tion = D). 
 • HFOV: initial setting mean airway pressure 13–17 cm 
H 2 O, frequency 10 Hz,   p 30–50 cm H2O depending 
on chest wall vibration (grade of recommendation = D). 
 • After stabilization, the FiO 2 should be decreased if 
preductal saturation is above 95% (grade of recom-
mendation = D). 
 Further Management in the Intensive Care Unit 
 Monitoring 
 Heart rate, invasive blood pressure and pre- and post-
ductal saturation should be monitored routinely.
 Hemodynamic Management 
 Hemodynamic management should be aimed at 
achieving appropriate end-organ perfusion determined 
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by heart rate, capillary refill, urine output and lactate lev-
els. If the heart rate is within the normal range, capillary 
refill is below 3 s, urine output is over 1.0 ml/kg/h, lactate 
concentration is below 3 mmol/l and there are no symp-
toms of poor perfusion, no inotropic support is required. 
 If there are signs of poor perfusion or if the blood pres-
sure is below the normal level for gestational age with
a preductal saturation below 80%, echocardiography 
should be performed to determine whether the poor per-
fusion is due to hypovolemic or cardiogenic shock. If 
there is hypovolemia, saline fluid therapy should be start-
ed (10–20 ml/kg NaCl 0.9% up to 3 times during the first 
1–2 h). If necessary, this should be followed by inotropic 
therapy. Hydrocortisone may be used for treatment of hy-
potension after conventional treatment has failed  [41] . In 
case of poor perfusion, vasopressor therapy should be 
started. In case of cardiogenic shock, as demonstrated by 
dysfunction of the left and/or right ventricle, inotropic 
agents should be considered  [42] . 
 Recommendations 
 • If symptoms of poor perfusion and/or blood pressure 
below the normal level for gestational age occur and 
are associated with preductal saturation below 80%, 
echocardiographic assessment should be performed 
(grade of recommendation = D). 
 • In case of hypovolemia, isotonic fluid therapy 10–20 
ml/kg NaCl 0.9% up to 3 times during the first 2 h may 
be given and inotropics should be considered (grade of 
recommendation = D) . 
 Pulmonary Hypertension Management 
 The physiological basis of pulmonary hypertension in 
infants with CDH is a decreased number of pulmonary 
arterial structures associated with significant adventitial 
and medial wall thickening due to an increased amount 
of smooth muscle cells in pulmonary arteries of all sizes, 
with abnormal intra-acinar arterioles. As a result, elevat-
ed pulmonary vascular resistance may lead to right-to-
left shunting after birth. This may result in hypoxemia 
and a difference in pre- and postductal oxygen satura-
tion. However, absence of a pre- and postductal gradient 
in oxygenation does not exclude the diagnosis of pulmo-
nary hypertension in the newborn since the right-to-left 
shunting may occur predominantly through the fora-
men ovale rather than through the ductus arteriosus. 
Therefore, 2-dimensional echocardiography performed 
within the first 24 h after birth remains one of the best 
modalities for the real-time assessment of pulmonary ar-
terial diameter and right heart function  [43–45] . Espe-
cially in severe cases of pulmonary hypertension, a car-
diac ultrasound may help to evaluate right ventricular 
dysfunction and/or right ventricular overload, which 
can also lead to left ventricular dysfunction. In patients 
with CDH, left ventricular dysfunction, either caused by 
right ventricular overload or a relative underdevelop-
ment of the left ventricle, is associated with a poor prog-
nosis  [46] . 
 If preductal saturations fall below 85% and there are 
signs of poor organ perfusion, treatment of pulmonary 
hypertension should be initiated by optimizing blood 
pressure. Adequate intravascular volume should be 
maintained with intravenous fluids as described above. 
Transfusion of packed red blood cells may be required 
to optimize tissue oxygen delivery. No studies show ev-
idence of increasing systemic vascular resistance to treat 
right-to-left shunting, but a number of centers advise 
using inotropics such as dopamine, dobutamine and 
epinephrine to maintain blood pressure at the normal 
levels for gestational age. Most recent publications ad-
vise to keep the systemic blood pressure over 40 mm Hg 
 [47] . One study successfully used norepinephrine to in-
crease systemic blood pressure in neonates with PPHN 
 [48] . 
 If pulmonary hypertension persists, pulmonary vaso-
dilator therapy should be given, with inhaled nitric oxide 
(iNO) as the first therapeutic choice. Endogenous nitric 
oxide regulates vascular tone by relaxation of vascular 
smooth muscle cells. In several studies, iNO produces 
potent and selective pulmonary vasodilation. In neo-
nates with PPHN, iNO improves oxygenation and de-
creases the need for ECMO. The largest randomized 
controlled trial of early iNO therapy in infants with 
PPHN due to CDH did not demonstrate a beneficial ef-
fect for iNO  [49] . The immediate short-term improve-
ments in oxygenation seen in some treated infants may 
be of benefit, however, for transport or the bridging pe-
riod to ECMO. At an oxygenation index of 20 or higher 
and/or a pre- and postductal saturation difference of 10% 
or more, iNO may be given for at least 1 h  [50] . Studies 
to date have not reported a consistent effect according to 
iNO dose  [51, 52] . Therefore, this needs further prospec-
tive study.
 If there is no or an insufficient response to iNO, intra-
venous prostacyclin or prostaglandin E1 should be con-
sidered. In recent case reports, these agents have been 
used successfully in treating pulmonary hypertension in 
neonates with and without CDH  [53–57] . The effects of 
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treatment for pulmonary hypertension may be best ad-
dressed by repeated cardiac evaluation  [46] . A 10–20% 
reduction in the pre- and postductal saturation difference 
or a 10–20% increase in PaO 2 , however, may be used as 
guidance in evaluating the course of pulmonary hyper-
tension  [58] .
 In the presence of systemic or suprasystemic pulmo-
nary artery pressure, the right ventricle might be over-
loaded, as demonstrated by enlargement of the right ven-
tricle and a leftward shift of the interventricular septum. 
This can lead to insufficient filling of the left ventricle 
and poor systemic perfusion. To protect the right ven-
tricle from excessive overload due to increased afterload, 
re-opening of the ductus arteriosus might be performed 
 [46] . 
 Sildenafil, a phosphodiesterase 5 inhibitor, has been 
used in the treatment of pulmonary hypertension in 
adults and in the management of postoperative pulmo-
nary hypertension in children with CDH  [59, 60] . Case 
reports in newborns with CDH suggest some improve-
ment in oxygenation and cardiac output from sildenafil 
alone or in combination with iNO  [60] . Currently, there 
are no randomized controlled trials studying the use of 
phosphodiesterase inhibition in infants with CDH, al-
though a recent open-label study reported on pharmaco-
kinetics in neonates treated with sildenafil  [61] . Other 
pulmonary vasodilators that have been used in pulmo-
nary hypertension in infants include endothelin antago-
nists and tyrosine kinase inhibitors  [62–67] . The consor-
tium recommends that sildenafil and other pulmonary 
vasodilators should only be used in the chronic phase of 
pulmonary hypertension in CDH because there is no ev-
idence that this helps in the acute phase in infants with 
CDH.
 Recommendations 
 • Perform echocardiography within the first 24 h after 
birth (grade of recommendation = D). 
 • Blood pressure support should be given to maintain 
arterial blood pressure levels at normal levels for ges-
tational age (grade of recommendation = D). 
 • iNO should be considered if there is evidence of extra-
pulmonary right-to-left shunting and the oxygenation 
index is above 20 and/or the saturation difference is 
more than 10% (grade of recommendation = D). 
 • In case of suprasystemic pulmonary artery pressure 
and right-to-left shunting through the foramen ovale, 
i.v. prostaglandin E1 has to be considered (grade of 
recommendation = D). 
 Extracorporeal Membrane Oxygenation 
 The role of ECMO in the treatment of infants with 
CDH is still unclear  [68] . In nonrandomized trials, 
ECMO has been reported to improve survival in infants 
with CDH  [69, 70] . In some reports, oxygenation index, 
alveolar-arterial O 2 difference or a combination of both 
is used as a selection criterion for ECMO. In other re-
ports, ECMO is considered if there is poor systemic per-
fusion with sustained hypoxemia with inadequate oxy-
gen delivery and persistent metabolic acidosis. Some cen-
ters only consider ECMO in infants with CDH if they 
show an adequate amount of lung parenchyma suggested 
by a period of adequate preductal oxygenation and/or 
ventilation  [71] . The use of ECMO has decreased  [22] , and 
is now more often used in preoperative stabilization  [72] . 
Reports of stabilization and subsequent repair on ECMO 
have highlighted the benefit of delaying surgery and do-
ing it after ECMO rather than on ECMO, particularly 
among high-risk infants  [73] . A meta-analysis of retro-
spective studies suggests that the introduction of ECMO 
has improved survival in infants with CDH  [74] . A meta-
analysis of randomized controlled trials with small sam-
ple sizes indicated a reduction in early mortality with 
ECMO, but no long-term benefit  [74] . 
 Criteria for ECMO (Grade of Recommendation = D):  
 • Inability to maintain preductal saturations  1 85% or 
postductal saturations  1 70%. 
 • Increased PaCO 2 and respiratory acidosis with pH
 ! 7.15 despite optimalization of ventilatory management. 
 • Peak inspiratory pressure  1 28 cm H 2 O or mean air-
way pressure  1 17 cm H 2 O is required to achieve satu-
ration  1 85%. 
 • Inadequate oxygen delivery with metabolic acidosis as 
measured by elevated lactate  6 5 mmol/l and pH  ! 7.15. 
 • Systemic hypotension, resistant to fluid and inotropic 
therapy, resulting in urine output  ! 0.5 ml/kg/h for at 
least 12–24 h. 
 • Oxygenation index (mean airway pressure  ! FiO 2  ! 
100/PaO 2 )  6 40 consistently present.  
 Timing of Surgical Repair and Postoperative 
Management 
 Survival rates in infants with CDH undergoing surgi-
cal repair after preoperative stabilization range from 79 
to 92%  [4, 34, 35, 75] . There are controversies about the 
timing of the surgical repair in patients who require 
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ECMO therapy. Early studies reported a high rate of hem-
orrhagic complications and high mortality when bleed-
ing developed  [73, 76] . A retrospective study from the 
CDH registry showed increased survival among patients 
who undergo repair of CDH after ECMO therapy relative 
to those who undergo repair while on ECMO  [77] . The 
routine use of a chest tube postoperatively has been aban-
doned, as an effusion usually quickly fills the pleural cav-
ity after repair. Moreover, this promotes infectious con-
tamination of the pleural space without any benefits, 
such as acceleration of ipsilateral lung expansion, postop-
eratively. In individual cases, a pleural effusion after re-
pair may compromise pulmonary function and ventila-
tion, necessitating chest tube insertion  [78] . 
 Recommendations 
 • Surgical repair of the defect in the diaphragm should 
be performed after physiological stabilization, defined 
as follows (grade of recommendation = D): 
 – mean arterial blood pressure normal for gestation-
al age; 
 – preductal saturation levels of 85 to 95% SaO 2 on 
fractional inspired oxygen below 50%;  
 – lactate below 3 mmol/l; and 
 – urine output more than 2 ml/kg/h. 
 • No routine chest tube placement (grade of recommen-
dation = D). 
 • Repair on ECMO may also be considered (grade of 
recommendation = D). 
 Sedation and Analgesia 
 A wide range of sedation and analgesia practices has 
been described. Most centers use opioid analgesics such 
as morphine sulfate or fentanyl. Neuromuscular blocking 
is sometimes used in cases of asynchronous breathing. 
Although there is no specific evidence in infants with 
CDH, neuromuscular blocking is associated with several 
major side-effects and should be avoided  [79] . The in-
fant’s condition using validated analgesia and sedation 
scoring systems, such as the COMFORT behavior score 
 [80] , should be regularly assessed.
 Recommendations 
 • Infants should remain sedated and monitored using 
validated analgesia and sedation scoring systems 
(grade of recommendation = D). 
 • Neuromuscular blocking agents should be avoided if 
possible (grade of recommendation = D). 
 Fluid Management and Parenteral Feeding 
 Restrictive fluid management in the first 24 h consists 
of 40 ml/kg/day of fluids, including medication, with ad-
ditional saline fluid therapy for intravascular filling. 
Thereafter, fluid and caloric intake should be increased 
based on clinical condition. Glucose, lipids and proteins 
should be given according the ESPGHAN/ESPEN guide-
lines  [81] . Diuretics should be given in case of a positive 
fluid balance, aiming for diuresis of 1–2 ml/kg/h. 
 Recommendations 
 • 40 ml/kg/day including medication for the first 24 h, 
intake increases thereafter (grade of recommenda-
tion = D). 
 • Diuretics should be considered in case of a positive 
fluid balance, aim for diuresis of 1–2 ml/kg/h (grade 
of recommendation = D). 
 Enteral Feeding and Gastroesophageal Reflux 
 Nutritional morbidity remains a problem in survivors 
of CDH during infancy and early childhood, particularly 
gastroesophageal reflux ranging from 20 to 84% during 
the first year of life  [82] . In survivors of CDH, gastro-
esophageal reflux may be treated both by antireflux med-
ication and by surgical intervention. No prospective 
studies are available on the specific type of antireflux 
medication. Other common sequelae are oral aversion 
and need for tube enteral feeding. No prospective studies 
are available on the type of antireflux mediation. 
 Recommendation 
•  Enteral feeding should be started postoperatively 
combined with antireflux medication (grade of rec-
ommendation = D).
 Conclusion 
 The European task force for CDH (CDH EURO Con-
sortium) has agreed on a protocol of standardized post-
natal treatment guidelines. This protocol was a prereq-
uisite for a multicenter randomized trial of ventilation 
modes in infants with CDH (VICI-trial, www.vicitrial.
com). At present, this protocol cannot be more than a 
consensus document because data from multicenter 
randomized controlled trials are lacking. The consor-
tium prepared these consensus guidelines with the aim 
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of providing neonatologists and pediatric intensive care 
physicians with a protocolized European treatment 
strategy. Use of this protocol will also contribute to 
more valid comparisons of patient data in multicenter 
studies and to the identification of areas for further re-
search. It was beyond the scope of these consensus 
guidelines to describe long-term follow-up in infants 
with CDH. However, long-term follow-up in children 
with CDH is highly important because approximately 
87% of survivors of CDH have longer lasting associated 
morbidities, such as pulmonary, gastrointestinal and 
neurological problems  [83] . The American Academy of 
Pediatrics Section on Surgery and the Committee on Fe-
tus and Newborn published a comprehensive plan for 
the detection and management of these associated mor-
bidities  [84] . 
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